Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria by Hassan, A. A. et al.
153
© 2011, Korean Society for Parasitology
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
INTRODUCTION
About 1.2 million Nigerians are reported blind while 4.25 
million adults aged 40 years and over have moderate to severe 
impairment or blindness [1,2]. River blindness is one of the 
common causes of blindness and has been a scourge for many 
years in the developing world, particularly in Sub-Saharan Af-
rica. However, tremendous success has been achieved in com-
bating against river blindness following the discovery and de-
velopment of ivermectin (trade name Mectizan®) in 1987. Mec-
tizan® has a major drawback, according to the Mectizan® Ex-
pert committee/The Mectizan® Donation Program and World 
Health Organization (WHO) [3,4], those suffering from on-
chocerciasis who simultaneously possess a high intensity of 
Loa loa infection could potentially suffer from severe adverse 
effects (SAEs), including neurological reactions, such as en-
cephalopathy. Several studies reported distribution of L. loa 
and prevalences of human loiasis in the vegetational zones of 
Southwestern Nigeria [5-11]. Levels of adverse outcomes of 
treatment with ivermectin have been reported from areas of 
co-endemicity of onchocerciasis with loiasis or lymphatic fila-
riasis [12-17]. Yet ivermectin remains the microfilaricide of 
choice in community-directed interventions. The Mectizan 
Donation Program commended the effectiveness and safe dis-
tribution of ivermectin [3]. This is not without some kind of 
limitations which thus led to emphasis on increasing the level 
of awareness among the target communities for onchocerciasis 
and lymphatic filariasis treatment with ivermectin. 
Enhancing the success story of African Programme for On-
chocerciasis Control (APOC), it was further recommended 
that the prevalence of L. loa and the risk of SAEs be assessed 
during or before commencement of ivermectin distribution 
on a community basis (www.mectizan.org/loarecs.asp). Ijebu-
North area of southwestern Nigeria has been reached by the 
annual ivermectin treatments. Hence, the need for assessing 
the risk status of loiasis endemicity and SAEs to the mass treat-
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Abstract: A total of 286 individuals from 3 selected communities (Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo) of Ijebu-
North, southwestern Nigeria were examined for Loa loa microfilaremia using finger prick blood smear, between December 
2008 and March 2009. Rapid assessment procedure for loiasis (RAPLOA) was used to obtain information, from 187 Ijebu-
Igbo residents, on adverse reactions experienced from retrospective treatments with ivermectin and history of eye worm. 
Only 33.9% of the respondents reported having had a history of eye worm while 33.2% had microfilaremia. The demo-
graphic factor of gender was not significant determinants of the prevalence (P>0.05) while age was significant (P<0.05). 
The highest prevalence of eye worm history and microfilaremia were recorded in 61-70 and 15-20 years of age catego-
ries, respectively. Ijebu-Igbo had 27.3% eye worm history, 32.1% microfilaremia, and the highest intensity of 140 microfi-
lariae (mf)/ml. Ipakodo area had the highest eye worm history of 54.4% and the highest intensity of 420 mf/ml. Areedi-Aje 
had the highest occurrence of 45.2% microfilaremia and the highest intensity of 460 mf/ml. Predictably, Areedi-Aje and 
Ipakodo areas were high risk communities. The low intensity of L. loa infection with an insignificant (2.1%; P>0.05) ad-
verse reactions from 187 subjects involved in the retrospective ivermectin administration confirmed that ivermectin deliv-
ery may be considered safe. The community-directed treatment with ivermectin (CDTI) programme was most probably 
responsible for the low prevalence and intensity. 
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ment with ivermectin program of Ijebu-North area is increas-
ing. The objective of this study was to determine the current 
prevalence and intensity of loiasis in 3 communities in Ijebu-
North as well as to investigate the suitability of community-di-
rected treatment with ivermectin (CDTI) and the risk of SAEs 
in the study area.
MATERIALS AND METHODS
Study area and population
Ijebu-North area of southwestern Nigeria lies between lati-
tude (Lat) 6.2° and 7.8° N and longitude (Long) 3.0° and 5.0°, 
within the rain forest vegetational zone. The climatic condi-
tion is a tropical pattern with rainy season starting in March 
and ending in November followed by a dry season. The mean 
annual rainfall varies from 128 cm in the southern part of the 
area to 105 cm in the northern area. Average monthly temper-
ature ranges from 23˚C to 32˚C. Ijebu-North area covers an area 
of about 1,250 km
2 and has its headquarters at Ijebu-Igbo. The 
people are mainly Ijebus (Yorubas). The study involved 3 com-
munities; Ijebu-Igbo, Areedi-Aje, and Ipakodo/Ojokodo envi-
rons, which are 10, 17, and 13 km, respectively from Ago-Iwoye 
(Lat N 6° 56´ 46.92´´, Long E 3° 55´ 55.09´´), the state university 
town (Fig. 1). Human population estimate at the time of the 
study was approximately 1,000, 500, and 1,000, respectively. 
The Ijebu-Igbo study group was primarily students, lecturers, 
technical, and administrative workers, while the inhabitants of 
the 2 villages were primarily subsistent farmers with few trad-
ers at Ipakodo.
History of community-directed treatment with ivermectin 
in the study villages and exclusion criteria
The Ijebu-North local government area had annual mass 
ivermectin administration against onchocerciasis, at the time 
of observation, Ijebu-Igbo was reached with a second round of 
oral treatment, while Areedi-Aje and Ipakodo areas were reach-
ed for the first time. The health workers in charge of ivermectin 
distribution administered an optimal dose of 150 μg/kg body 
weight (that is, 2, 3 or 4 tablets depending on individual wei-
ght) were administered leaving out children aged less than 5 
years or who weighed less than 15 kg or less than 95 cm tall, 
nursing mothers, menstruating women, and persons with se-
vere illness or nervous disorders.
Fig. 1. Map of Ijebu-North local government area showing the study sites.
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Advocacy and ethical clearance
Preliminary visits were made to the administrative head-
quarters of Ijebu-North local government area and approval 
was granted for the study protocol prior to commencement of 
the study. The local government health officer on ivermectin 
distribution and the representative from UNICEF assisted 
throughout the study. The purpose and methods of the study 
was discussed at length with the different community heads 
and head of school, who all gave their informed consent be-
fore the individual villagers were approached. The school com-
munity at Ijebu-Igbo was assembled by the school authority, 
for proper information dissemination. Only individuals who 
consented to participate were mobilized at the subsequent vis-
its. Local knowledge about eye worm was recorded by admin-
istration of community level questionnaire to key informants 
(village heads/elders). Individuals who were 15 years and above, 
who had been resident in the localities for at least 5 years were 
informed of the objective of the study and their right to refuse 
to participate.
Study design and rapid assessment for loiasis 
(questionnaire)
A randomized cross-sectional survey was carried out be-
tween December 2008 and March 2009. A total of 286 partici-
pants were enrolled for the study; 187, 57, and 42 from Ijebu-
Igbo, Ipakodo area, and Areedi-Aje, respectively. Individual 
questionnaire, designed according to rapid assessment proce-
dure for loiasis (RAPLOA) guidelines [18], to elicit responses 
to establish the history of eye worm and duration of eye worm 
episode (between 1-7 days) were administered with the help 
of an interpreter. The year of treatments with ivermectin dur-
ing previous drug administration programme, adverse reac-
tion, type, and duration of reaction following, if any, was re-
corded for individuals interviewed.
Determination of parasitological prevalence
A 0.08 ml sample of finger-prick blood was collected on a 
clean slide, from each study participant between 11:00 and 
15:00 hr. The use of 1 sterile blood lancet per participant was 
ensured, and used lancets were disinfected and properly dis-
posed. Thick blood smears were made on the slide using stan-
dard procedures for Leishman’s stain [19]. The slides were ex-
amined microscopically with ×10 objective. Identification of L. 
loa microfilariae was according to standard guidelines for diag-
nosis of microfilaremia [20]. Microfilariae were counted and 
intensities were expressed as the number of microfilariae per 
ml blood.
Data analysis
Data were entered in summary of survey results form. Statis-
tical Package for Social Science (SPSS) (version 10 package) 
was used to determine the relationship of rapid assessment of 
L. loa indices with occurrence of adverse reactions following 
treatment with ivermectin. Percentage of people who had con-
firmed eye worm experience was determined for each locality. 
Classification of the communities as ‘high risk’ (>40% report 
of eye worm history) or ‘low risk’ (<40% report of eye worm 
history) was according to recommended classification [21].
RESULTS
Preliminary observations
Local name for the eye worm in the study sites was “aran 
oju” meaning worm of the eye. A 80% of the interviewees al-
ready had awareness of loiasis.
Prevalence of loiasis
A 33.9% of respondents reported history of Loa eye worm 
infection, while 33.2% had Loa microfilaremia; these 2 preva-
lences were not significantly different (P>0.05). Ipakodo/
Ojokodo had the highest prevalence of eye worm history, 54.4%, 
while Ijebu-Igbo had the least, 27.3%. The prevalence of mi-
crofilaremia was the highest in Areedi-Aje, followed by Ijebu-
Igbo and the least was Ipakodo area (Table 1). Females had a 
Table 1. Prevalence of loiasis in 3 communities of Ijebu-North area
Locality No. of residents 
examined
History of eye worm Infection (%) Blood examination (%) Range of microfilarial 
density Yes  No Yes No
Areedi-Aje   42 15 (35.7)   27 (64.3) 19 (45.2)   23 (57.8) 60-460
Ipakodo/Ojokodo   57 31 (54.4)   26 (45.6) 16 (28.1)   41 (71.9) 80-420
Ijebu-Igbo 187 51 (27.3) 136 (72.7) 60 (32.1) 127 (67.9) 20-140 
Total 286 97 (33.9) 189 (66.1) 95 (33.2) 191 (66.8)156   Korean J Parasitol Vol. 49, No. 2: 153-159, June 2011
high prevalence of Loa infection. However, there were no sig-
nificant differences (P>0.05) in the history of eye worm infec-
tion and microfilaremia in relation to gender (Table 2). The 
age category of 61-70 years had the highest prevalence of eye 
worm history (66.7%) and the lowest prevalence of microfila-
remia (11.1%), while the age category of 15-20 years recorded 
the lowest prevalence of eye worm history (28.3%) and the 
highest prevalence of 41.3% loa microfilaremia (Fig. 2). The 
difference between prevalences in age groups 15-20 and 61-70 
years was statistically significant (P<0.05). 
Intensity of loiasis
Loa microfilarial (mf) intensity among interviewees ranged 
from 20-460 mf/ml. At the community level, mf intensity ran-
ges were 60-460 mf/ml, 80-420 mf/ml, and 20-140mf/ml at 
Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo, respectively 
(Table 1). 
Adverse reactions following retrospective treatment with 
ivermectin
Adverse outcomes were reported in only 4 participants (Ta-
ble 3). Chi-square test showed insignificant differences be-
tween males and females (P>0.05). Adverse events reported 
were itching on the head for 1 day in 1 patient, dizziness for 2 
days in another, stomach ache for 2 days in 1 subject, and worm 
movement along the white part of the eyes for 1 month in yet 
another. Pre-treatment densities of microfilariae for the 2.1% 
reactors are shown in Table 3. The nature of adverse events was 
mild, and no case of severe adverse reaction, involving the ner-
vous system, was reported.
DISCUSSION
Ivermectin remains the prominent safe and efficacious mi-
crofilaricide but because it has little effect on the adult worm, 
retreatment of individuals annually is recommended [22]. The 
recent past years witnessed continuous administration of iver-
mectin in Ijebu-North of southwestern Nigeria as treatment 
for either onchocerciasis or lymphatic filariasis or both. All 3 
surveyed communities, already reached by masstreatment with 
ivermectin, showed a high level (80%) awareness of eye worm 
infection. The same local name for L. loa eye worm was avail-
able, which further showed there is widespread knowledge of 
the Loa eye worm. 
There are reports of the long lasting effect of ivermectin on L. 
loa microfilaremia [13] and observations that a history of iver-
mectin treatment for longer than 3 years tended to decrease 
the probability that a subject had a detectable L. loa mf [23]. 
These factors could explain why prevalence of 33.9% history 
of eye worm (restricted definition) was observed in the present 
study. This prevalence falls under the ‘low risk’ category be-
cause a prevalence of more than 40% eye worm history is the 
threshold for a high risk of adverse reactions [21,24,25].
Table 2. Gender-based prevalence of loiasis
Gender
History of Loa eye worm; 
% (count)
Loa microfilaremia; 
% (count)
Yes No Positive Negative
Female 31.3 (50)     68.8 (110)      32.5 (52)    67.5 (108)
Male 37.3 (47)     62.7  (79)      34.1 (43)    65.9  (83)
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Fig. 2. Prevalence of Loa eye worm history and Loa microfilare-
mia in relation to age group. 
Table 3. Adverse consequences following ivermectin treatment
No. Gender Age Nature of adverse reaction
Loa loa eye worm 
history
Loa microfilarial density 
(mf/ml)
1 Female 41 Itching on the head for 1 day No 80
2 Female 22 Dizziness for 2 days Yes 100
3 Male 24 Stomach ache for 2 days No 60
4 Male 44 Worm moving along the white part of the eyes for more than 7 days Yes 120  Hassan et al.: Assessment of loiasis and ivermectin masstreatment in Nigeria   157
The community related prevalence observed in the present 
study indicated that there is need for determination of the en-
demicity status of L. loa in individual community qualified for 
CDTI, before the commencement of drug administration. A 
significant variation ranging from 27.3%, 35.7%, to 54.4% 
prevalence of loiasis was observed at the communities. The 
implication is that while Ijebu-Igbo fell under ‘low risk’ of ad-
verse reaction, Ipakodo and environs came under a ‘high risk’ 
area, all within the same zone with 33.9% prevalence. Thus, 
putting the usage of 40% cut off point for safe distribution of 
ivermectin in a bioecological zone at risk of false threshold 
above which there is a high risk of adverse reactions.
A linear relationship between the prevalence and intensity 
of L. loa infection was reported in 102 surveyed villages [25], 
which indicated a high intensity of infection (>8,000 mf/ml) 
above 5% which corresponded to a prevalence of microfilare-
mia in thick blood film of >20%. The prevalence of eye worm 
according to the restricted definition was reported to clearly 
increase with the prevalence of microfilaremia. The cut-off 
point of a 40% prevalence of eye worm corresponded to a 20% 
prevalence of microfilaremia at the community level. The in-
stability of the population in the present study and exclusion 
of less than 5 years residents as expected, with a suspected pos-
sible neglected reservoir of Loa parasites could account for why 
microfilaremia may be high or still be on the increase (33.2% 
prevalence against 33.9% prevalence of eye worm). However, 
the low intensity of infection ranging from 20-460 mf/ml show-
ed impact of CDTI in the study area.
Loiasis distribution status is not significantly gender-biased, 
but it is significantly age-related. Female participants showed 
higher positive Loa microfilaria than males, which were not 
significantly different (P>0.05) and could only suggest that fe-
males were more exposed to Chrysops vectors than males in the 
study area. On the contrary, earlier studies in Nigeria had re-
ported that males were likely than females to present with Loa 
microfilaremia [11,26,27]. The mechanisms underlying the 
gender bias are still unknown; experimental infections in ani-
mal models have demonstrated gender differences in suscepti-
bility to, or the development of, filarial infections [28]. Epide-
miological data from central Cameroon revealed that preva-
lence of Loa microfilaremia was significantly higher in male 
subjects than in females [23], the authors however concluded 
based on level of exposure (higher or low) that males and fe-
males do not have the same pattern of response to exposure 
and that gender and exposure were associated with the pres-
ence of L. loa microfilaremia. Some other surveys had reported 
that males were more likely to present with Loa microfilaremia 
than females [23,29]. 
Earlier workers [30] did not find any significant association 
between gender and microfilaremic status; however, some ob-
served lower prevalences of Loa microfilaremia in females. A 
question of interest should be the peculiarity of the locality in 
terms of sociocultural attitudes and practices. The observations 
of the present study could only confirm the possibility of equal 
vector exposure both on the farmlands visited by males and 
females and temporary human settlements in the immediate 
vicinity of the vectors.
There is an inverse relationship between the age and body 
immunity of a man [31]. The higher the age, the more suscep-
tible to infections man becomes. The possibility of occupa-
tional hazard was also suggested as majority of the adults in 
the study were farmers and highly exposed to the vector trans-
mitting the disease. The present study also confirmed that eye 
worm history was more prevalent in the age group of 61-70 
years. In addition, the significant differences observed in the 
prevalence by age could be due to differences in vector expo-
sure. An indication pointed out by earlier investigators [23] re-
ported indications that an effect of ivermectin may be to para-
lyze the Loa mf. This according to the previous report may fa-
cilitate the action of inflammatory cells against the mf, which 
could then be destroyed in the blood vessels or in the lym-
phatic system. There was a confirmation of the previous report 
of long-term effect of ivermectin on reproductive activity, or 
longevity, of the adult worms [32] which also indicated that 
ivermectin may also reduce the production of new mf [23]. 
This could explain the present observation of least mf in the 
age group of 61-70 years who had been treated with ivermec-
tin in the past. An expected increase in the prevalence of mi-
crofilaremia with age was reported by earlier workers [23,30]. 
A further suggestion explained that the risk of an individual 
being infected, via the bite of an infected Chrysops, increases 
with time, and that a person who has become microfilaremic 
remains so throughout life. Continued drug administration 
had been reported to result in reduced intensity of adverse re-
actions, prevalence, and intensity of microfilariae [33]. Fur-
thermore, the probability of marked reduction of loiasis trans-
mission by a single dose of ivermectin had been reported [34]. 
The microfilaremic status of the subjects in the present study 
could be further explained by the reported observation that 
microfilariae are never detected in samples of peripheral blood 158   Korean J Parasitol Vol. 49, No. 2: 153-159, June 2011
from many people who are known to have been infected with 
L. loa and have experienced occult loiasis [35,36]
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